JILL COOPER: Open Payments
NPI 1376722520 · STANFORD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,923 in 78 payments from 28 companies in 2025. Trend: 2023 $2,841 · 2024 $1,318 · 2025 $1,923
Food & beverage: $1,873Education: $50
| Company | Payments | Amount |
|---|---|---|
| Daiichi Sankyo Inc. | 18 | $376 |
| Celgene Corporation | 9 | $224 |
| Merck Sharp & Dohme LLC | 7 | $182 |
| Janssen Biotech, Inc. | 4 | $149 |
| AstraZeneca Pharmaceuticals LP | 6 | $149 |
| ABBVIE INC. | 3 | $75 |
| GlaxoSmithKline, LLC. | 3 | $73 |
| ADC THERAPEUTICS AMERICA, INC. | 2 | $67 |
| ARRAY BIOPHARMA INC | 2 | $59 |
| KYOWA KIRIN, INC. | 2 | $57 |
Products named: INJECTAFER, KEYTRUDA, Enhertu, REBLOZYL, DARZALEX, OPDIVO, ZYNLONTA, POTELIGEO.
Industry payments across CA — which companies pay providers there.
